Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
2 "Jung Ho Bae"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
COVID-19
Article image
Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis
Hye Jun Kim, Sang Jun Lee, Soonok Sa, Jung Ho Bae, Gyuseon Song, Chae Won Lee, Ju Hee Kim, Sung Ryul Shim, Myunghee Hong, Hyun Wook Han
Diabetes Metab J. 2023;47(3):356-365.   Published online March 6, 2023
DOI: https://doi.org/10.4093/dmj.2022.0129
  • 6,163 View
  • 285 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Little is known about the adverse events (AEs) associated with coronavirus disease 2019 (COVID-19) vaccination in patients with type 2 diabetes mellitus (T2DM).
Methods
This study used vaccine AE reporting system data to investigate severe AEs among vaccinated patients with T2DM. A natural language processing algorithm was applied to identify people with and without diabetes. After 1:3 matching, we collected data for 6,829 patients with T2DM and 20,487 healthy controls. Multiple logistic regression analysis was used to calculate the odds ratio for severe AEs.
Results
After COVID-19 vaccination, patients with T2DM were more likely to experience eight severe AEs than controls: cerebral venous sinus thrombosis, encephalitis myelitis encephalomyelitis, Bell’s palsy, lymphadenopathy, ischemic stroke, deep vein thrombosis (DVT), thrombocytopenia (TP), and pulmonary embolism (PE). Moreover, patients with T2DM vaccinated with BNT162b2 and mRNA-1273 were more vulnerable to DVT and TP than those vaccinated with JNJ-78436735. Among patients with T2DM administered mRNA vaccines, mRNA-1273 was safer than BNT162b2 in terms of the risk of DVT and PE.
Conclusion
Careful monitoring of severe AEs in patients with T2DM may be necessary, especially for those related to thrombotic events and neurological dysfunctions after COVID-19 vaccination.

Citations

Citations to this article as recorded by  
  • Herbal-based therapeutics for diabetic patients with SARS-Cov-2 infection
    Yousef Rasmi, Ighli di Bari, Shah Faisal, Munima Haque, Pornanong Aramwit, Aline da Silva, Elmira Roshani Asl
    Molecular Biology Reports.2024;[Epub]     CrossRef
  • Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
    Sasha E. Larsen, Susan L. Baldwin, Rhea N. Coler
    International Journal of Infectious Diseases.2023; 130: S47.     CrossRef
  • Neurological Disorders following COVID-19 Vaccination
    Ying Yang, Lisu Huang
    Vaccines.2023; 11(6): 1114.     CrossRef
  • Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis (Diabetes Metab J 2023;47:356-65)
    Hye Jun Kim, Sung Ryul Shim, Myunghee Hong, Hyun Wook Han
    Diabetes & Metabolism Journal.2023; 47(5): 717.     CrossRef
  • Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis (Diabetes Metab J 2023;47:356-65)
    Jung Hun Ohn
    Diabetes & Metabolism Journal.2023; 47(5): 715.     CrossRef
Association of Serum Cystatin C with Metabolic Syndrome and Its Related Components in Korean Adults.
Sun Young Kim, Sang Heon Song, Yun Kyung Jeon, Ji Ryang Kim, Jung Ho Bae, Sang Soo Kim, Soo Hyung Lee, Seok Man Son, In Ju Kim, Yong Ki Kim, Yang Ho Kang
Korean Diabetes J. 2008;32(5):409-417.   Published online October 1, 2008
DOI: https://doi.org/10.4093/kdj.2008.32.5.409
  • 2,870 View
  • 33 Download
  • 3 Crossref
AbstractAbstract PDF
BACKGROUND
Serum cystatin C has been reported as a better marker than serum creatinine for estimation of kidney function and may be associated with cardiovascular disease. The aim of this study was to elucidate the association of serum cystatin C with metabolic syndrome (MS), a constellation of cardiovascular risk factors, and its related components and the usefulness of serum cystatin C for the cardiovascular risk assessment. METHODS: 1,468 healthy subjects (814 men and 655 women), who visited health promotion center of Pusan National University Hospital for routine medical checkup were included. MS was defined by modified, revised National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III criteria. RESULTS: Mean serum cystatin C value was 0.87 +/- 0.17 mg/L. In partial correlation analysis adjusted by age, sex and Glomerular Filtration Rate (GFR), cystatin C was associated with most of metabolic parameters and especially had significant positive correlation with waist circumference (r = 0.215), triglyceride (TG) (r = 0.141), diastolic blood pressure (BP) (r = 0.116), and correlated negatively with high density lipoprotein (HDL) cholesterol (r = -0.152) (all P < 0.001). There were increasing trends of prevalence of MS with the increase of quartiles of cystatin C and as the number of MS components increased, cystatin C values significantly increased. Serum cystatin C was also significantly increased in MS (0.90 +/- 0.19 mg/L vs. 0.86 +/- 0.16 mg/L). In stepwise multiple regression analysis including the components of MS, Waist circumference, diastolic BP, triglyceride, and HDL cholesterol were independent determinants of serum cystatin C, but with creatinine, only waist circumference was independent determinant. CONCLUSIONS: Serum cystatin C was closely associated with MS and its related cardiovascular risk factors and might be useful as a tool of cardiovascular risk assessment.

Citations

Citations to this article as recorded by  
  • Cystatin C in Patients of Metabolic Syndrome and its Correlation with the Individual Components of Metabolic Syndrome
    Sunita Aghade, Jayshree S Bavikar, Pragati S Kadam, Reshakiran J Shendye
    Indian Journal of Medical Biochemistry.2019; 23(2): 293.     CrossRef
  • Cystatin C as a Predictor for Diabetes according to Glycosylated Hemoglobin Levels in Korean Patients
    Eon Ju Jeon, Ji Hyun Lee
    Diabetes & Metabolism Journal.2016; 40(1): 32.     CrossRef
  • Association of Obesity with Serum Cystatin C in Korean Adults
    Yang Ho Kang
    The Korean Journal of Obesity.2015; 24(4): 199.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP